Paper Details

  1. Home
  2. Paper Details

Risk Factors for Adverse Birth Outcomes in the PROMISE 1077BF/1077FF Trial.

Author: ChakhtouraNahida, ChiBenjamin H, ChipatoTsungai, FarhadMona, FentonTerry, FowlerMary Glenn, McIntyreJames A, MoodleyDhayendre, NevrekarNeetal, OworMaxensia, QinMin, SaidiFriday, SebikariDorothy, StringerJeffrey S A, TahaTaha E, TheronGerhard, ViolariAvy

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This multicountry trial found that women initiating a protease inhibitor-based antiretroviral treatment regimen had a significantly higher risk of low birth weight and preterm delivery compared to those receiving ZDV alone. Tenofovir/emtricitabine was associated with more severe outcomes.
Paper Details　
Original Abstract of the Article :
In the multicountry PROMISE 1077BF/1077FF trial, the risk of low birth weight (LBW; <2500 g) and preterm delivery (PTD; <37 weeks) was significantly higher among women initiating a protease inhibitor-based antiretroviral treatment (ART) regimen than those receiving ZDV alone. Among those assigned to...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/31295174

データ提供：米国国立医学図書館（NLM）

Examining the Impact of Antiretroviral Treatment on Pregnancy Outcomes

Antiretroviral therapy (ART) is essential for managing HIV infection and preventing transmission. This study investigates the impact of different ART regimens on pregnancy outcomes in women with HIV.

The researchers analyzed data from a multicountry clinical trial that compared the effects of protease inhibitor-based ART regimens to those of a regimen containing zidovudine (ZDV) alone. They found that women initiating a protease inhibitor-based regimen had a significantly higher risk of low birth weight (LBW) and preterm delivery (PTD) compared to those receiving ZDV alone. Among those assigned to a protease inhibitor regimen, tenofovir/emtricitabine was associated with the more severe outcomes of very low birth weight (VLBW) and very preterm delivery (VPTD) compared to zidovudine/lamivudine.

Understanding the Risks Associated with ART

This study provides important information on the risks associated with different ART regimens during pregnancy, highlighting the need for careful selection of treatment strategies to optimize both maternal and fetal health.

The Importance of Individualized Care for Pregnant Women with HIV

The study underscores the importance of individualizing care for pregnant women with HIV, considering the potential risks and benefits of different ART regimens.

Dr.Camel's Conclusion

The journey to a healthy pregnancy for women with HIV is a complex and delicate one. This study highlights the need for a careful and individualized approach to ART regimens, navigating the desert of potential risks and benefits to ensure the best outcomes for both mothers and babies.

Date :
  1. Date Completed 2020-04-13
  2. Date Revised 2023-09-20
Further Info :

Pubmed ID

31295174

DOI: Digital Object Identifier

NIHMS1526676

Related Literature

Article Analysis
・Effects of zdv
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.